JP2025511969A5 - - Google Patents
Info
- Publication number
- JP2025511969A5 JP2025511969A5 JP2024559691A JP2024559691A JP2025511969A5 JP 2025511969 A5 JP2025511969 A5 JP 2025511969A5 JP 2024559691 A JP2024559691 A JP 2024559691A JP 2024559691 A JP2024559691 A JP 2024559691A JP 2025511969 A5 JP2025511969 A5 JP 2025511969A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- combination
- optionally
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329096P | 2022-04-08 | 2022-04-08 | |
| US63/329,096 | 2022-04-08 | ||
| US202263368499P | 2022-07-15 | 2022-07-15 | |
| US63/368,499 | 2022-07-15 | ||
| PCT/US2023/065433 WO2023196899A2 (en) | 2022-04-08 | 2023-04-06 | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511969A JP2025511969A (ja) | 2025-04-16 |
| JP2025511969A5 true JP2025511969A5 (cg-RX-API-DMAC7.html) | 2026-04-14 |
Family
ID=88243701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559691A Pending JP2025511969A (ja) | 2022-04-08 | 2023-04-06 | Pi3キナーゼ阻害剤とチェックポイント阻害剤の併用を用いた、多形膠芽腫、及び乳癌を含むその他の癌をスクリーニング及び治療するための方法及び製品 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250228863A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504264A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511969A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250044594A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119654165A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023249640A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255739A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012457A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196899A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| RU2016148441A (ru) * | 2014-05-21 | 2018-06-22 | Ф. Хоффманн-Ля Рош Аг | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом |
| US20190038713A1 (en) * | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2020215037A1 (en) * | 2019-04-18 | 2020-10-22 | The Regents Of The University Of Michigan | Combination with checkpoint inhibitors to treat cancer |
| PH12023550160A1 (en) * | 2020-07-31 | 2023-09-18 | Exelixis Inc | Combinations for the Treatment of Cancer |
-
2023
- 2023-04-06 US US18/854,796 patent/US20250228863A1/en active Pending
- 2023-04-06 CA CA3255739A patent/CA3255739A1/en active Pending
- 2023-04-06 CN CN202380044911.1A patent/CN119654165A/zh active Pending
- 2023-04-06 JP JP2024559691A patent/JP2025511969A/ja active Pending
- 2023-04-06 EP EP23785623.2A patent/EP4504264A4/en active Pending
- 2023-04-06 AU AU2023249640A patent/AU2023249640A1/en active Pending
- 2023-04-06 WO PCT/US2023/065433 patent/WO2023196899A2/en not_active Ceased
- 2023-04-06 KR KR1020247036529A patent/KR20250044594A/ko active Pending
-
2024
- 2024-10-07 MX MX2024012457A patent/MX2024012457A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marei et al. | Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired | |
| Mun et al. | Tumor-treating fields: a fourth modality in cancer treatment | |
| O'Donnell et al. | The promise of neoadjuvant immunotherapy and surgery for cancer treatment | |
| EP4096671B1 (en) | Combination therapy for treating abnormal cell growth | |
| Katz et al. | HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery | |
| DuRoss et al. | Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer | |
| Berenson et al. | Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study | |
| EP2359828A1 (en) | HDAC inhibitors and hormone targeted drugs for the treatment of cancer | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| Wilson et al. | Advanced basal cell carcinoma: what dermatologists need to know about treatment | |
| Li et al. | The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge | |
| EP4376828A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2022022392A (ja) | ヒトにおける固形腫瘍の処置のためのC.novyi | |
| Kunos et al. | Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2–IIIB cervical cancer | |
| Curigliano et al. | Alpelisib in combination with everolimus±exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study | |
| JP2019510785A (ja) | 癌を処置する方法 | |
| Kuboki et al. | PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study | |
| Inetas‐Yengin et al. | Related mechanisms, current treatments, and new perspectives in meningioma | |
| Zhou et al. | Therapeutic potential of tumor treating fields for malignant brain tumors | |
| Lee et al. | Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study | |
| Kurdi et al. | Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors | |
| Li et al. | Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer | |
| Kunos et al. | Phase I trial of triapine–cisplatin–paclitaxel chemotherapy for advanced stage or metastatic solid tumor cancers | |
| KR20110128916A (ko) | 췌장암의 치료 | |
| Khan et al. | Intermittent MEK inhibition for the treatment of metastatic uveal melanoma |